In conclusion, the combination of Immunepotent CRP with cyclophosphamide triggers synergistic cell death, involving loss of mitochondrial membrane potential, an increase in ROS production, caspase activation, morphological changes, and caspase-independent cell death in breast cancer cells, while ICRP did not affect CTX-cytotoxicity in PBMC, allowing to reduce the CTX doses. This evidence concerns the gene CRP and breast carcinoma.